Therapeutic Sequencing in Metastatic Renal Cell Carcinoma
Kidney Cancer · 2017
DOI: 10.3233/kca-170006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney Cancer, 2017. Verfasst von Manuel Caitano Maia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The influx of multiple novel therapeutic options in the mRCC field has brought a challenge for treatment sequencing in this disease. In the past few years, cabozantinib, nivolumab and the combination of lenvatinib and everolimus have been approved in the second-line setting. As there is no direct comparison between these agents and the studies have failed to show improved benefit among a biomarker-selected patient population, appropriate patient selection based on clinical factors for individualized therapy is critical. Herein we provide a comprehensive overview of current data from each agent through the discussion of disease biology, clinical trials, potential biomarkers and distilling future perspectives in the field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Zitieren
APA
Maia, M. C., Dizman, N., Salgia, M., & Pal, S. K. (2017). Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. Kidney Cancer. https://doi.org/10.3233/kca-170006
Vancouver
Maia MC, Dizman N, Salgia M, Pal SK. Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. Kidney Cancer. 2017. doi:10.3233/kca-170006
BibTeX
@article{Maia2017,
author = {Maia, Manuel Caitano and Dizman, Nazli and Salgia, Meghan and Pal, Sumanta Kumar},
title = {Therapeutic Sequencing in Metastatic Renal Cell Carcinoma},
journal = {Kidney Cancer},
year = {2017},
doi = {10.3233/kca-170006}
}
EUVIMED